#1 Clinical Trials Search in Europe

IBANDRONIC ACID

Clinical trials investigating IBANDRONIC ACID are studying bone health treatments in people with osteogenesis imperfecta, a condition that makes bones break more easily. These trials look at whether treatment plans can lower fracture risk and how well they work compared with usual care. They also include adults and other patients receiving different bone medicines as part of study care.

Table of contents

Trial overview

The trial record linked to IBANDRONIC ACID is a completed interventional study, which means researchers gave study treatments and then measured what happened.[1] The study ID is 2024-519705-36-00 and it was run as a Phase 3 trial with 360 planned participants.[1]

Although the trial title lists several bone medicines, the record shows that IBANDRONIC ACID was one of the study drugs included in the intervention list.[1]

Condition studied

The trial studied osteogenesis imperfecta, a condition that makes bones fragile and easier to break.[1] This is why the main focus of the study was fracture prevention and bone health.[1]

Study design and phase

This was a Phase 3 study, which is a later stage of clinical research used to test how well a treatment works in a larger group of people.[1] The study was event-driven, meaning it was planned to continue until a set number of fracture events had occurred.[1]

The primary outcome was expected to be reached after an average follow-up of 62 months, based on the number of fractures observed.[1]

Who participated

The trial planned to include 360 participants.[1] The source data do not give a more detailed age range or other eligibility rules, so the safest description is that the study involved people with osteogenesis imperfecta who were suitable for this Phase 3 bone study.[1]

What the study measured

The main endpoint was the proportion of participants experiencing a clinical fracture that was confirmed by x-ray or other imaging.[1] An endpoint is the main result a trial measures to see whether the treatment works.[1]

This endpoint is important because fractures are the key problem in osteogenesis imperfecta, and confirmed imaging helps make sure the outcome is counted correctly.[1]

Treatment comparison and standard care

The brief summary says the study compared a treatment plan of teriparatide followed by zoledronic acid with standard care.[1] Standard care in this trial could mean no active treatment or treatment with bisphosphonates, depending on patient and provider preference.[1]

The intervention list also included several bone medicines, including IBANDRONIC ACID, but the source does not explain the exact role of each listed medicine in the final comparison.[1]

What these trial results mean for patients

For patients, the most important point is that this research was designed to see whether a treatment strategy could lower the chance of broken bones in people with osteogenesis imperfecta.[1] Because the trial is completed, the study question has already been tested, but the source data provided here do not include the final results.[1]

The trial does not provide enough detail to say that IBANDRONIC ACID alone was the only study treatment, so it should be understood as one of the listed medicines in a broader bone research setting.[1]

Trial ID Phase Condition studied Status Enrollment
2024-519705-36-00 Phase 3 Osteogenesis imperfecta Completed 360

FAQ

  • What are clinical trials of IBANDRONIC ACID trying to find out? They are looking at whether treatment plans that include IBANDRONIC ACID-related care can reduce fractures and improve bone outcomes. The main focus is on how many people have a fracture confirmed by x-ray or other imaging.
  • Who may take part in these trials? The study data describe people with osteogenesis imperfecta. Enrollment is planned for 360 participants, so the trial is designed for a fairly large group.
  • What phase is the IBANDRONIC ACID trial in? The trial is in Phase 3. This means it is a later-stage study that tests how well a treatment works in a larger group of people.
  • What condition is being studied? The condition is osteogenesis imperfecta. This is a disorder in which bones are fragile and can fracture more easily.
  • What is the main outcome being measured? The main outcome is the proportion of participants who have a clinical fracture confirmed by x-ray or other imaging. The study is event-driven, meaning it ends after a set number of fracture events have happened.

Ongoing Clinical Trials on IBANDRONIC ACID

  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Ireland The Netherlands

Glossary

  • Osteogenesis imperfecta: A condition that makes bones fragile and more likely to break.
  • Clinical fracture: A broken bone that is seen or confirmed during medical care.
  • X-ray: A type of imaging test that shows bones and can confirm a fracture.
  • Other imaging: Other scan tests used to look at bones and confirm a fracture.
  • Phase 3: A later stage of clinical research that studies how well a treatment works in a larger group.
  • Interventional study: A study where researchers give a treatment and observe the results.
  • Enrollment: The number of people planned to join a study.
  • Standard care: The usual treatment a patient would receive outside the study.
  • Bisphosphonates: A group of bone medicines mentioned in the study as part of standard care options.
  • Event-driven study: A study that ends after a planned number of events, such as fractures, has happened.

References